Literature DB >> 2163064

Supratentorial malignant glioma: an analysis of radiation therapy in 178 cases.

Y Shibamoto1, J Yamashita, M Takahashi, T Yamasaki, H Kikuchi, M Abe.   

Abstract

To analyze treatment results of supratentorial malignant gliomas in the megavoltage era, all the histologic specimens were reviewed and glioblastoma multiforme (GBM) was distinguished from anaplastic astrocytoma (AA) by the presence of necrosis. Among those who had completed radiotherapy and who had been followed for at least one year, 135 GBM and 43 AA patients were found. The median survival time (MST) after operation was 12 months for GBM and 18 months for AA. The 5-year survival rate was 0.9% for GBM and 18% for AA. The size of radiation field had little influence on survival time; MST was 12 months for GBM patients treated with a local field covering tumor plus less than 2 cm margin, 12 months for those treated with a generous field (2 cm or more margin), and 13 months for those treated to whole brain. Also for AA, whole brain radiation did not prolong survival. Initial relapse of GBM and AA developed within the irradiated volume in 86% of the cases treated with a generous field. Whole brain radiation seemed useless for the treatment of malignant gliomas. Survival time appeared to be dose-dependent; MST was 10, 13, and 16 months for GBM patients who received 45-57, 57-63, and 63-72 Gy, respectively. Extensive surgical resection was associated with a better prognosis in GBM. AA patients 60 years old or older had a poorer prognosis than younger patients, but age was not a significant prognostic factor for GBM. Chemotherapy appeared to prolong survival slightly without improving long-term survival.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1990        PMID: 2163064     DOI: 10.1016/0167-8140(90)90018-r

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  19 in total

Review 1.  Operative techniques for gliomas and the value of extent of resection.

Authors:  Nader Sanai; Mitchel S Berger
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 2.  Altered therapy schedules in postoperative treatment of patients with malignant gliomas. Twenty year experience of the Maria Skłodowska-Curie Memorial Center in Kraków, 1973-1993.

Authors:  B Gliński; P Dymek; J Skołyszewski
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

3.  Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; D F Nelson; A J Fischbach; C H Chang; M Rotman; S O Asbell
Journal:  J Neurooncol       Date:  1992-03       Impact factor: 4.130

Review 4.  Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma.

Authors:  Aniket S Wadajkar; Jimena G Dancy; David S Hersh; Pavlos Anastasiadis; Nhan L Tran; Graeme F Woodworth; Jeffrey A Winkles; Anthony J Kim
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-11-04

Review 5.  Maximizing safe resection of low- and high-grade glioma.

Authors:  Shawn L Hervey-Jumper; Mitchel S Berger
Journal:  J Neurooncol       Date:  2016-05-12       Impact factor: 4.130

6.  Validation of the Medical Research Council and a newly developed prognostic index in patients with malignant glioma: how useful are prognostic indices in routine clinical practice?

Authors:  Fadime Akman; Rachel A Cooper; Mehmet Sen; Yildiray Tanriver; Süleyman Kentli
Journal:  J Neurooncol       Date:  2002-08       Impact factor: 4.130

7.  Pediatric glioblastoma: clinico-radiological profile and factors affecting the outcome.

Authors:  Kuntal Kanti Das; Anant Mehrotra; Anup P Nair; Shaleen Kumar; Arun K Srivastava; Rabi N Sahu; Raj Kumar
Journal:  Childs Nerv Syst       Date:  2012-08-19       Impact factor: 1.475

8.  Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts.

Authors:  Tomoko Ozawa; Sergei M Gryaznov; Lily J Hu; Krisztina Pongracz; Raquel A Santos; Andrew W Bollen; Kathleen R Lamborn; Dennis F Deen
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

9.  Defining Glioblastoma Resectability Through the Wisdom of the Crowd: A Proof-of-Principle Study.

Authors:  Adam M Sonabend; Brad E Zacharia; Michael B Cloney; Aarón Sonabend; Christopher Showers; Victoria Ebiana; Matthew Nazarian; Kristin R Swanson; Anne Baldock; Henry Brem; Jeffrey N Bruce; William Butler; Daniel P Cahill; Bob Carter; Daniel A Orringer; David W Roberts; Oren Sagher; Nader Sanai; Theodore H Schwartz; Daniel L Silbergeld; Michael B Sisti; Reid C Thompson; Allen E Waziri; Zoher Ghogawala; Guy McKhann
Journal:  Neurosurgery       Date:  2017-04-01       Impact factor: 4.654

Review 10.  Receptor "hijacking" by malignant glioma cells: a tactic for tumor progression.

Authors:  Jian Huang; Keqiang Chen; Wanghua Gong; Ye Zhou; Yingying Le; Xiuwu Bian; Ji Ming Wang
Journal:  Cancer Lett       Date:  2008-04-22       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.